@article {7066,
	title = {Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study},
	journal = {Clinical Colorectal Cancer},
	volume = {15},
	year = {2016},
	note = {Export Date: 18 February 2017References: Andr{\'e}, T., Boni, C., Navarro, M., Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial (2009) J~Clin Oncol, 27, pp. 3109-3116;Haller, D.G., Tabernero, J., Maroun, J., Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer (2011) J~Clin Oncol, 29, pp. 1465-1471; 
Ducreux, M., Bennouna, J., Hebbar, M., Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (2011) Int J Cancer, 128, pp. 682-690; 
Krishnan, A.V., Goldstein, D., Friedlander, M., Kiernan, M.C., Oxaliplatin-induced neurotoxicity and the development of neuropathy (2005) Muscle Nerve, 32, pp. 51-60; 
Park, S.B., Goldstein, D., Lin, C.S.Y., Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity (2009) J~Clin Oncol, 27, pp. 1243-1249; 
Grothey, A., Oxaliplatin-safety profile: neurotoxicity (2003) Semin Oncol, 30 (4), pp. 5-13; 
Pietrangeli, A., Leandri, M., Terzoli, E., Jandolo, B., Garufi, C., Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up (2006) Eur Neurol, 56, pp. 13-16; 
Park, S.B., Lin, C.S., Krishnan, A.V., Goldstein, D., Friedlander, M.L., Kiernan, M.C., Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility (2011) Oncologist, 16, pp. 708-716; 
Beijers, A.J.M., Mols, F., Vreugdenhil, G., A~systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration (2014) Support Care Cancer, 22, pp. 1999-2007; 
Labianca, R., Nordlinger, B., Beretta, G.D., Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2013) Ann Oncol, 24, pp. 64-72; 
ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmhttps://cancerstaging.org/references-tools/quickreferences/pages/default.aspxBurakgazi, A.Z., Messermith, W., Vaidya, D., Hauer, P., Hoke, A., Polydefkis, M., Longitudinal assessment of oxaliplatin-induced neuropathy (2011) Neurology, 77, pp. 980-986; 
Binder, A., Stengel, M., Maag, R., Pain in oxaliplatin-induced neuropathy{\textemdash}sensitisation in the peripheral and central nociceptive system (2007) Eur J Cancer, 43, pp. 2658-2663; 
Baron, R., Mechanisms of disease: neuropathic pain{\textemdash}a clinical perspective (2006) Nat Clin Pract Neurol, 2, pp. 95-106; 
Kokotis, P., Schmelz, M., Papagianni, A.E., Zambelis, T., Karandreas, N., Objective assessment of C-fiber function by electrically induced axon reflex flare in patients with axonal and demyelinating polyneuropathy (2013) J~Clin Neurophysiol, 30, pp. 422-427; 
de Gramont, A., Figer, A., Seymour, M., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer (2000) J~Clin Oncol, 18, pp. 2938-2947; 
Raymond, E., Faivre, S., Woynarowski, J.M., Oxaliplatin: mechanism of action and antineoplastic activity (1998) Semin Oncol, 25 (2), pp. 4-12; 
Andr{\'e}, T., Boni, C., Mounedji-Boudiaf, L., Oxaliplatin, 5-fluorouracil, leucovorin as adjuvant treatment for colon cancer (2004) N~Engl J Med, 350, pp. 2343-2351; 
Grothey, A., Goldberg, R.M., A~review of oxaliplatin and its clinical use in colorectal cancer (2004) Expert Opin Pharmacother, 5, pp. 2159-2170; 
Cavaletti, G., Tredici, G., Petruccioli, M.G., Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat (2001) Eur J Cancer, 37, pp. 2457-2463; 
Screnci, D., McKeage, M.J., Galettis, P., Hambley, T.W., Palmer, B.D., Baguley, B.C., Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs (2000) Br J Cancer, 82, pp. 966-972; 
Pasetto, L.M., D{\textquoteright}Andrea, M.R., Rossi, E., Monfardini, S., Oxaliplatin-related neurotoxicity: how and why? (2006) Crit Rev Oncol Hematol, 59, pp. 159-168
},
	month = {2016},
	pages = {e133 - e140},
	abstract = {Micro-Abstract Acute oxaliplatin neurotoxicity and chronic sensory cumulative neuropathy were investigated in a long-term study of 31 consecutive patients with advanced colorectal cancer. Our results improve the knowledge of acute neurotoxicity and support the finding of the persistence of the sensory nerve deficits for years after the cessation of oxaliplatin therapy. {\textcopyright} 2016 Elsevier Inc.},
	keywords = {Acute neurotoxicity, Chronic persistent neuropathy, Long-term study, Neurophysiologic follow-up, Oxaliplatin},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962091528\&doi=10.1016\%2fj.clcc.2016.02.009\&partnerID=40\&md5=9cc55485d87d6f0c6ecf0d195b72d4ee},
	author = {Kokotis, P. and Schmelz, M. and Kostouros, E. and Karandreas, N. and Dimopoulos, M.-A.}
}
